IXICO contract with new large global pharma

RNS Number : 8322H

IXICO plc

08 December 2020

 

IXICO plc

("IXICO" or the "Company")

IXICO contract with new large global pharma

IXICO selected by new large global pharma for orphan drug clinical trial

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, has secured a contract for neuroimaging solutions with a new, large global pharmaceutical company. The Phase IIB trial will investigate an orphan drug designated clinical asset for the treatment of Huntington's disease.

Huntington's disease (HD) is a progressive and devastating neurodegenerative disorder for which no disease-modifying therapies currently exist. Orphan drug designations help biopharmaceutical sponsors undertake valuable investigations and develop treatments for rare and complex conditions such as HD. Since its inception in 2004, IXICO has had an extensive track record of delivering innovative neuroimaging solutions to support clients in optimising their pipelines for rare diseases.

This contract was included in management's expectations of performance for the current financial year but adds to the Company's strong order book.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "We are delighted to be chosen to take part in this HD study to advance development of promising medical treatments for this devastating rare disease. This contract and new partnership will further endorse our breakthrough neuroimaging technologies with large pharma sponsors across the full spectrum of the drug development pathway."

For further information please contact:

IXICO plc			[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales
Walbrook PR Ltd	[phone]
Paul McManus / Lianne Cawthorne /		[e-mail]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com   and follow us on Twitter @IxicOplc  

 

END

 

 

CNTFSEFWWESSELE